华硼中子HyBorSys BNCT全流程解决方案：突破卡脖子技术，铸就肿瘤治疗新标杆

Core Viewpoint - Huaborn Neutron Technology (Hangzhou) Co., Ltd. is a leader in the field of Boron Neutron Capture Therapy (BNCT) in China, having successfully developed a comprehensive BNCT solution that achieves a breakthrough in core technology localization [1][8]. Group 1: Company Overview - The company was founded by Professor Wang Sheng from Xi'an Jiaotong University and has assembled a top-tier team centered around national high-level talents [1]. - It has established a complete industrial system supported by a research and production base of nearly 10,000 square meters and has undertaken multiple national-level research projects [1]. - As a national high-tech enterprise, the company has gained significant market and capital recognition, with its innovative achievements receiving widespread attention from the industry and media [1]. Group 2: Technology and Product Development - The HyBorSys BNCT solution developed by the company consists of three core modules: accelerator neutron source system, boron-targeted drugs, and treatment planning system [8]. - The technology has achieved several breakthroughs, including a neutron source proton beam power of 35KW, which is at an international leading level [8]. - The second-generation boron drug has completed pilot production with stable processes, and the third-generation drug is in the research and development stage [8]. - The treatment planning system is based on self-developed algorithms, ensuring precision while improving efficiency, supporting accurate dose calculations and target area planning [8]. Group 3: Clinical Applications and Market Potential - The BNCT solution offers a new non-invasive treatment option for difficult-to-treat tumors such as gliomas and head and neck tumors, typically requiring only 1-2 treatments, allowing patients to leave the hospital within 1-2 days [8]. - The solution has shown superior efficacy compared to traditional methods in treating head and neck tumors and recurrent gliomas, with over a hundred domestic and international patents applied for [8]. - The estimated single treatment cost is expected to be significantly lower than that of proton and heavy ion therapies, effectively reducing the economic burden on patients [8]. - The company has established collaborations with multiple hospitals and has been selected as a key product for review by the National Medical Products Administration, receiving important policy support [8]. Group 4: Future Outlook - The company aims to fill the gap in high-end BNCT medical equipment in China and promote the formation of a trillion-level innovative industrial cluster [9]. - With the smooth progress of clinical trials and continuous technological iterations, the HyBorSys BNCT solution is expected to benefit more cancer patients and contribute Chinese wisdom and solutions to global tumor precision treatment [9].